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Purpose or Objective: Stereotactic ablative radiotherapy 
(SABR) for liver metastases is currently accepted as a 
standard treatment option for patients with liver metastases. 
Multiple studies have demonstrated high rates of local control 
and low risk of serious toxicities. However, there is limited 
prospective patient-reported health-related quality of life 
data (HRQoL). Herein, we report the acute HRQoL changes in 
patients treated with SABR for liver metastases. 
 
Material and Methods: A prospective study was performed to 
measure HRQoL changes in patients treated with SABR to 1-3 
hepatic metastases. Doses of 30- 60 Gy in 3-5 fractions were 
delivered as per institutional policy depending on tumor 
location, histology and size. Changes in patients’ self-
reported HRQoL were measured using the European 
Organisation for Research and Treatment of Cancer (EORTC) 
Quality of Life Questionnaire–Core 15 Palliative (C15) at 
baseline (T0) and first follow-up (T1: 6 - 8 weeks post-SABR). 
The C15 consists of 15 questions; 2 multi-item symptom 
scales along with 5 single item symptom scales and a final 
overall QoL question. A significant change in HRQoL was 
defined as [T0 score-T1 score] > 0.5SD, where SD was the 
standard deviation of baseline values for each scale. For the 
overall QoL question, a significant change was defined by a 
10-point or greater change from baseline. 
 
Results: Fifty patients were included. Median age at 
treatment was 65 (40-88) years. Median BED10 was 98 Gy. 
The 4 most common primary sites of cancer were: gastro-
intestinal (29), breast (9), renal cell (4) and lung (4). All 
patients were Child-Pugh score A. Nine patients had previous 
hepatectomies for liver metastases. Thirty-one patients had 
oligometastatic disease (≤5 metastases)  and 19 had 
oligoprogression (≤5 metastases progressing). Forty -seven 
patients filled the C15 at T1 (94%). The majority of patients 
did not report a significant change in any of the C15 scales 
(table 1). For the overall QoL, 64% of the patients reported 
no significant change at T1, 24% had deterioration and 13% 
had an improvement. 
 
 
 
Conclusion: SABR offers a non-invasive option for liver 
metastases ablation. Acute patient-reported outcomes, as 
measured by C-15, for patients with liver metastases treated 
with SABR seem favourable. Longer follow-up is needed. 
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Purpose or Objective: Treating locally advanced pancreatic 
cancer (LAPC) remains a challenging issue. Chemotherapy or 
chemoradiotherapy alone have not demonstrated their 
efficacy. A strategy combining chemotherapy and 
chemoradiotherapy seems promising. Our retrospective 
analysis aims to evaluate effectiveness and tolerability of 
induction chemotherapy with Folfirinox followed by 
chemoradiotherapy in patients with LAPC. 
 
Material and Methods: Nineteen patients treated for LAPC 
between Mars 2010 and February 2015 were retrospectively 
identified. These patients with unresectable disease, were 
initially treated with Folfirinox and then received a 
chemoradiotherapy with capecitabine or gemcitabine in case 
of stable disease. Survival was estimated with Kaplan Meier 
method. 
 
Results: Median number of cycles achieved for Folfirinox was 
5. Following chemotherapy, all patients had stable disease 
and received chemoradiotherapy with capecitabine (53%) or 
gemcitabine (47%). Majority of patients (63%) received 
radiotherapy at a dose of 50.4 Gray in 28 fractions. Toxicities 
are acceptable: three cases of grade 3 nausea / vomiting, 
three cases of grade 3 asthenia and three cases of grade 3 
diarrhea were described during chemotherapy. No grade 3 
toxicity was identified during chemoradiotherapy. The 
median follow-up time was 9 months (1-43 months). Survival 
rates were 93.8% at six months, 52.7% at 1 year and 21.1% at 
2 years. Disease free survival rates were 35.3% at six months, 
7.8% at 1 year and 0% at 2 years. Local recurrence free 
survival rates were 75.3% at six months, 47.3% at 1 year and 
31.6 at 2 years. Distant recurrence free survival rates were 
34.3% at six months, 18.3% at 1 year and 9.2% at 2 years. At 
the end of the therapeutic procedure, one patient received 
surgical resection. 
 
Conclusion: Induction chemotherapy with Folfirinox followed 
by chemoradiotherapy in locally advanced pancreatic 
adenocarcinoma seems effective and allows very promising 
overall and progression free survival rates. Larger studies 
would be needed to conclusively confirm these observations. 
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Purpose or Objective: Gastrointestinal (GI) toxicity impedes 
dose escalation in radiotherapy for pancreatic cancer and 
limits local tumour control. Clinical data on tolerance doses 
for the organs of the proximal digestive system remain 
sparse. We analysed patterns of toxicity in patients treated 
with concomitant chemoradiotherapy (gemcitabine and 
cisplatin) with nelfinavir (hypoxia modifier) to identify 
associated dosimetric factors and establish predictive cut-off 
values to inform radiotherapy planning. 
 
Material and Methods: Dose-volumes and acute toxicity data 
were analysed for 21 patients treated for locally-advanced 
pancreatic cancer in a prospective phase II clinical trial 
(ARCII, EudraCT 2008-006302-42). Radiotherapy comprised 
50.4Gy in 28 daily fractions to the tumour and elective lymph 
nodes followed by a sequential boost to the primary tumour 
of 9Gy in 5#. Univariate analysis was performed to 
investigate association of the dose-volume received by 
stomach and duodenum with RTOG upper GI toxicity 
symptoms, and of small-bowel with diarrhoea. Receiver 
Operating Characteristic analysis was used to identify 
